2021’s crystal ball: Six AI predictions from Aktana management that will shape a new commercial model.

France-based Servier and U.K.-based MiNA Therapeutics are partnering on small activating RNA (saRNA) therapies to treat neurological diseases

Stephen Byers, Ph.D., associate director and professor of oncology at Georgetown Lombardi, and his team published a paper in the journal Gastroenterology regarding their findings of a novel target for pancreatic cancer therapy.

Affinivax Inc., a clinical stage biopharmaceutical company pioneering the development of a novel class of vaccines with its MAPS (Multiple Antigen Presenting System) platform, announced the closing of a $226 million Series C financing.

Global health innovation leader W2O announced the acquisitions of tech-enabled companies Swoop and IPM.ai, further accelerating what is expected to be the company’s 20th consecutive year of double-digit revenue growth.

Swiss pharma giant Novartis AG is harnessing the power of Zurich-based Molecular Partners AG’s DARPin platform to develop two therapeutic candidates that could both be used to prevent and treat Covid-19 infection.

Full-service healthcare communications marketing agency MicroMass Communications launched the podcast series Intersect, which tells stories of behavioral science in action.

Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.

Javelin Biotech announced a three-year collaboration with Pfizer to design and build what could potentially be an industry-leading platform to evaluate ADME (absorption, distribution, metabolism and excretion) properties of small molecules.

Johnson & Johnson announced a major milestone as the company launched a large-scale, international Phase III trial for the Covid-19 vaccine candidate JNJ-78436735.